Differential association between apolipoprotein B and LDL cholesterol and cerebral atherosclerosis according to pre-stroke statin use

To reduce cardiovascular risk, low-density lipoprotein cholesterol (LDL-C) is the primary target of statin treatment, while apolipoprotein B (ApoB) is secondary. We investigated the association between atherosclerotic stenosis and LDL-C or ApoB levels and whether a difference in association exists a...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2023-04, Vol.371, p.14-20
Main Authors: Baik, Minyoul, Nam, Hyo Suk, Heo, Ji Hoe, Lee, Hye Sun, Kim, Young Dae
Format: Article
Language:English
Subjects:
Apolipoprotein B
Apolipoproteins
Apolipoproteins B
Atherosclerosis
Cholesterol, LDL
Constriction, Pathologic
Cross-Sectional Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Intracranial Arteriosclerosis - complications
Intracranial Arteriosclerosis - diagnostic imaging
Intracranial Arteriosclerosis - drug therapy
Ischemic stroke
Ischemic Stroke - complications
LDL cholesterol
Retrospective Studies
Risk Factors
Statin treatment
Stroke - complications
Stroke - epidemiology
Stroke - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To reduce cardiovascular risk, low-density lipoprotein cholesterol (LDL-C) is the primary target of statin treatment, while apolipoprotein B (ApoB) is secondary. We investigated the association between atherosclerotic stenosis and LDL-C or ApoB levels and whether a difference in association exists according to pre-admission statin use in ischemic stroke patients. This retrospective cross-sectional study included consecutive patients with acute ischemic stroke or transient ischemic attack who underwent lipid profile and angiographic testing. Patients were categorized into four groups according to stenosis location: normal, extracranial atherosclerotic stenosis (ECAS), intracranial atherosclerotic stenosis (ICAS), or ECAS + ICAS. Subgroup analyses were performed by pre-admission statin use. Of the 6338 patients included, 1980 (31.2%) were in the normal group, 718 (11.3%) in the ECAS group, 1845 (29.1%) in the ICAS group, and 1795 (28.3%) in the ECAS + ICAS group. Both LDL-C and ApoB levels were associated with every location of stenosis. A significant interaction was found between pre-admission statin use and LDL-C level (p for interaction
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2023.03.014